LncRNA SEMA3B‐AS1 suppresses the tumor‐initiating characteristics of triple negative breast cancer via engaging in MLL4‐mediated H3K4 trimethylation

Author:

Chen Debo12,Chen Zhishan3,Wang Zhitang12,Hong Chengye12,Wang Qinglan12,Yang Peidong12,Huang Zhidong12,Lian Weibin12,Huang Yiqin2,Fu Wei2,Li Junjing12,Hong Zhipeng12ORCID

Affiliation:

1. Department of Breast Surgery Affiliated Quanzhou First Hospital of Fujian Medical University Quanzhou Fujian China

2. The School of Clinical Medicine Fujian Medical University Fuzhou Fujian China

3. Department of General Surgery Nan'an Hospital Quanzhou Fujian China

Abstract

AbstractLong noncoding RNAs (lncRNAs) are crucial regulators of tumor‐initiating cells (TICs) and hold particular importance in triple negative breast cancer (TNBC). Yet, the precise mechanisms by which TIC‐associated lncRNAs influence TNBC remain unclear. Our research utilized The Cancer Genome Atlas Breast Cancer (BC) data set to identify prognostic lncRNAs. We then conducted extensive assays to explore their impact on the tumor‐initiating phenotype of TNBC cells and the underlying mechanisms. Notably, we found that low expression of lncRNA SEMA3B‐AS1 correlated with unfavorable survival in BC patients. SEMA3B‐AS1 was also downregulated in TNBC and linked to advanced tumor stage. Functional experiments confirmed its role as a TIC‐suppressing lncRNA, curtailing mammosphere formation, ALDH + TIC cell proportion, and impairing clonogenicity, migration, and invasion. Mechanistic insights unveiled SEMA3B‐AS1's nuclear localization and interaction with MLL4 (mixed‐lineage leukemia 4), triggering H3K4 methylation‐associated transcript activation and thus elevating the expression of SEMA3B, a recognized tumor suppressor gene. Our findings emphasize SEMA3B‐AS1's significance as a TNBC‐suppressing lncRNA that modulates TIC behavior. This study advances our comprehension of lncRNA's role in TNBC progression, advocating for their potential as therapeutic targets in this aggressive BC subtype.

Publisher

Wiley

Subject

Cancer Research,Molecular Biology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3